Hoth Therapeutics Advances Phase 2 Trial of HT-001 for EGFR-Inhibitor-Associated Rash
I'm PortAI, I can summarize articles.
Hoth Therapeutics Inc. is advancing its Phase 2 CLEER-001 clinical trial of HT-001 for EGFR-inhibitor-associated rash in oncology supportive care. The company also progresses its HT-KIT program for mast cell diseases, nearing IND-enabling toxicology study completion. Clinical data updates are expected as enrollment continues, with an IND filing planned. This AI-generated news brief is for informational purposes only and not financial advice.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments